Knight Therapeutics (GUD) News Today C$11.63 +0.02 (+0.17%) As of 04:00 PM Eastern Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends Knight Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Knight Therapeutics (TSE:GUD) Reaches New 52-Week High - Still a Buy?October 22, 2026 | americanbankingnews.comKnight Therapeutics Announces Regulatory Approval of NIKTIMVO in BrazilOctober 7, 2026 | marketscreener.comMKnight Therapeutics Announces Launch of TAVALISSE® in BrazilOctober 6, 2026 | markets.businessinsider.comKnight Therapeutics Inc.September 30, 2026 | barrons.comKyowa Kirin, Knight Therapeutics Enter Distribution Deal For POTELIGEO In Latin AmericaSeptember 29, 2026 | rttnews.comKyowa Kirin Signs Exclusive POTELIGEO Distribution Deal With KnightSeptember 29, 2026 | rttnews.comKyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin AmericaSeptember 29, 2026 | finance.yahoo.comKnight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)September 29, 2026 | markets.businessinsider.comKnight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing CompaniesSeptember 25, 2026 | markets.businessinsider.comKnight Therapeutics Gets Regulatory Approval for TAVALISSE in ColombiaSeptember 2, 2026 | finance.yahoo.comNotice of Knight Therapeutics' Second Quarter 2026 Results Conference CallJuly 30, 2026 | markets.businessinsider.comKnight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comKnight to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | markets.businessinsider.comTSX Value Picks Knight Therapeutics And 2 Other Stocks Estimated Below Intrinsic ValueMarch 25, 2026 | uk.finance.yahoo.comKnight Therapeutics advances chronic GvHD expansion strategyFebruary 27, 2026 | finance.yahoo.com3 TSX Growth Companies With Insider Ownership As High As 27%January 28, 2026 | finance.yahoo.comProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO(R) in Canada from KnightNovember 12, 2025 | barrons.comKnight Therapeutics Secures US$100 Million Credit Facility to Boost GrowthOctober 31, 2025 | msn.comKnight Therapeutics announces approval, launch of MINJUVI in ArgentinaOctober 30, 2025 | msn.comKnight Therapeutics Announces Filing of New Drug Submission for CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in CanadaJuly 18, 2025 | finanznachrichten.deEarnings call transcript: Knight Therapeutics Q1 2025 beats EPS forecastMay 10, 2025 | uk.investing.comWhy this value manager likes Knight Therapeutics but is changing the channel on Warner Bros. DiscoveryMarch 28, 2025 | theglobeandmail.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 2,500,000 SharesMarch 25, 2025 | insidertrades.comCollective, Knight at 52-Week Highs on NewsMarch 21, 2025 | baystreet.caSime Armoyan selling more Knight Therapeutics (GUD)March 20, 2025 | theglobeandmail.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 92,200 Shares of StockMarch 19, 2025 | insidertrades.comKnight Therapeutics price target raised to C$8 from C$7.50 at Raymond JamesMarch 12, 2025 | markets.businessinsider.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Buys 17,600 Shares of StockMarch 6, 2025 | insidertrades.comKnight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for OnicitJanuary 31, 2025 | finanznachrichten.deGot $4,000? 4 Healthcare Stocks to Buy and Hold ForeverJanuary 27, 2025 | fool.caSime Armoyan Purchases 90,300 Shares of Knight Therapeutics Inc. (TSE:GUD) StockNovember 16, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Buys 20,000 SharesNovember 12, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 300,000 SharesSeptember 22, 2024 | insidertrades.comAmal Khouri Sells 5,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockAugust 21, 2024 | insidertrades.comKnight Therapeutics Inc. (GUD.TO)August 12, 2024 | ca.finance.yahoo.comKnight Therapeutics earnings: here's what to expectAugust 7, 2024 | markets.businessinsider.comKnight Therapeutics Inc. (KHTRF)July 24, 2024 | finance.yahoo.comKnight Therapeutics Inc. (TSE:GUD) Senior Officer Amal Khouri Sells 10,000 SharesJuly 4, 2024 | insidertrades.comAmal Khouri Sells 20,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockJune 15, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Director Buys C$29,000.00 in StockJune 6, 2024 | insidertrades.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Director Sells 15,000 Shares of StockMay 30, 2024 | insidertrades.comGUD:CA Knight Therapeutics Inc.May 14, 2024 | seekingalpha.comKnight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call TranscriptMay 12, 2024 | seekingalpha.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 15,000 Shares of StockMay 9, 2024 | insidertrades.comKnight Therapeutics Announces Product Launch for IMVEXXY® in CanadaJanuary 4, 2024 | finance.yahoo.comKnight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaDecember 19, 2023 | finance.yahoo.comKnight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing CompaniesOctober 2, 2023 | finance.yahoo.comClosing Bell: Knight Therapeutics Inc flat on Thursday (GUD)September 14, 2023 | theglobeandmail.comKnight Therapeutics (KHTRF) Receives a Buy from RBC CapitalAugust 12, 2023 | markets.businessinsider.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsAugust 10, 2023 | theglobeandmail.com Knight Therapeutics Media Mentions By Week Knight Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GUD News Sentiment▼0.290.55▲Average Healthcare News Sentiment Knight Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GUD Articles This Week▼10▲GUD Articles Average Week Knight Therapeutics Trends on MarketBeatThis week vs. last weekPage Views901-7% Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BHC News CRON News DHT.UN News TLRY News FRX News WEED News ACB News CPH News CRDL News OGI News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Knight Therapeutics dated 10/7/2026. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, ju...Brownstone Research | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
